Additional baricitinib loading dose improves clinical outcome in COVID-19
Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for
high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of …
high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of …
JAK-STAT pathway inhibition and their implications in COVID-19 therapy
S Satarker, AA Tom, RA Shaji, A Alosious… - Postgraduate …, 2021 - Taylor & Francis
As the incidence of COVID-19 increases with time, more and more efforts are made to pave
a way out for the therapeutic strategies to deal with the disease progression. Inflammation …
a way out for the therapeutic strategies to deal with the disease progression. Inflammation …
Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …
Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies
Over the last 25 years, inhibition of Janus kinases (JAKs) has been pursued as a modality
for treating various immune and inflammatory disorders. While the clinical development of …
for treating various immune and inflammatory disorders. While the clinical development of …
Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19
Corona virus is quickly spreading around the world. The goal of viral management is to
disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms …
disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms …
[HTML][HTML] The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
Background The evidence of using JAK inhibitors among hospitalized patients with COVID-
19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of …
19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of …
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
L Walz, AJ Cohen, AP Rebaza, J Vanchieri… - BMC infectious …, 2021 - Springer
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has
emerged as a once-in-a-century pandemic, having already infected over 63 million people …
emerged as a once-in-a-century pandemic, having already infected over 63 million people …
Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19
W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …
JAK inhibition as a new treatment strategy for patients with COVID-19
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
outbreak of coronavirus disease 2019 (COVID-19) commenced across the world …
outbreak of coronavirus disease 2019 (COVID-19) commenced across the world …
Efficacy of combination therapy with the JAK inhibitor baricitinib in the treatment of COVID-19
BL Thoms, J Gosselin, B Libman, B Littenberg… - SN Comprehensive …, 2022 - Springer
Abstract Coronavirus disease-19 (COVID-19), resulting from infection with SARS-CoV-2,
spans a wide spectrum of illness. In severely ill patients, highly elevated serum levels of …
spans a wide spectrum of illness. In severely ill patients, highly elevated serum levels of …